-- Company Presentation Scheduled for June 8, 2016 at 1:00 PM PT --

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 26, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Gaurav Aggarwal, M.D., Chief Business Officer, will be presenting at the 2016 BIO International Convention being held at the Moscone Center in San Francisco, California from June 6-9, 2016. Ocera’s presentation will take place on Wednesday, June 8, 2016 in Room 1 at 1:00 PM Pacific Time. 

A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.

OCRX-G

Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
contact@ocerainc.com
919-328-1109

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.